Crossmark

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer

Crossref DOI link: https://doi.org/10.1186/s12967-018-1569-5

Published Online: 2018-07-16

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Green, Daniel S.

Nunes, Ana T.

David-Ocampo, Virginia

Ekwede, Irene B.

Houston, Nicole D.

Highfill, Steven L.

Khuu, Hanh

Stroncek, David F.

Steinberg, Seth M.

Zoon, Kathryn C.

Annunziata, Christina M. https://orcid.org/0000-0003-2033-6532
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02948426 at ClinicalTrials.gov

Documents that mention this clinical trial

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer
https://doi.org/10.1186/s12967-018-1569-5

405 A non-canonical role for CCL2 in T cell migration: improving dual-interferon-treated autologous monocytes as a therapy for ovarian cancer
https://doi.org/10.1136/jitc-2022-sitc2022.0405
Funding

Funding for this research was provided by:

National Cancer Institute (ZIA BC 011054)
License Information

Text and Data Mining valid from 2018-07-16

Version of Record valid from 2018-07-16
More Information

Article History

Received: 29 June 2018

Accepted: 3 July 2018

First Online: 16 July 2018

Document is current

Any future updates will be listed below